First, developing precision risk stratification tools requires integrating AID-specific parameters such as disease activity metrics (e.g., SLEDAI for lupus), CNS-penetrating autoantibody profiles, and dynamic inflammatory trajectories like IL-6 kinetics to predict individual vulnerability. This evidence concerns the gene IL6 and systemic lupus erythematosus.